Skip to Content
Not all colorectal cancer treatments are the same. Find out more >

Gleevec (imatinib) Disease Interactions

There are 7 disease interactions with Gleevec (imatinib):

Moderate

Bcr-Abl Tyrosine Kinase Inhibitors (Includes Gleevec) ↔ Cardiovascular Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Cardiovascular Disease

Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors. If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention. The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.

Moderate

Bcr-Abl Tyrosine Kinase Inhibitors (Includes Gleevec) ↔ Fluid Retention

Moderate Potential Hazard, Moderate plausibility

Applies to: Congestive Heart Failure, Pleural Effusion, Pulmonary Impairment, Fluid Retention

Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema. Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure. Monitor and manage patients using standards of care. Interrupt, reduce dose or discontinue therapy as necessary.

Moderate

Bcr-Abl Tyrosine Kinase Inhibitors- Bone Marrow Suppression

Moderate Potential Hazard, Moderate plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors. Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression. A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated. To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.

Moderate

Imatinib (Includes Gleevec) ↔ Gastrointestinal Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Gastrointestinal Perforation, Duodenitis/Gastritis

Imatinib has been sometimes associated with GI irritation, and it should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including fatalities, of gastrointestinal perforation. Caution should be used in patients with history of GI disorders.

Moderate

Imatinib (Includes Gleevec) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Patients with severe hepatic impairment tend to have higher exposure to both imatinib and its metabolite than patients with normal hepatic function, and dose might need to be adjusted accordingly. Additionally, there have been reports of hepatotoxicity both with short and long term use of imatinib. Liver function should be monitored before initiation of treatment and regularly during therapy. Dose reduction or interruption might be needed if laboratory abnormalities are found.

Moderate

Imatinib (Includes Gleevec) ↔ Hypothyroidism

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypothyroidism

Hypothyroidism cases have been reported in thyroidectomy patients undergoing levothyroxine replacement therapy during treatment with imatinib. Caution should be used in these patients and TSH levels should be monitored closely.

Moderate

Imatinib (Includes Gleevec) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The mean exposure to imatinib is increased in patients with renal impairment compared to those with normal renal function. Dose reductions are necessary in patients with moderate and severe renal impairment.

Gleevec (imatinib) drug Interactions

There are 856 drug interactions with Gleevec (imatinib)

Gleevec (imatinib) alcohol/food Interactions

There is 1 alcohol/food interaction with Gleevec (imatinib)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide